These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39362847)

  • 1. Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study.
    Gu L; Peng C; Liang Q; Huang Q; Lv D; Zhao H; Zhang Q; Zhang Y; Zhang P; Li S; Xu J; Chen L; Xie Y; Li J; Guo G; Zhang X; Wang B; Ma X
    Signal Transduct Target Ther; 2024 Oct; 9(1):264. PubMed ID: 39362847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
    Huang J; Wang Y; Xu F; Wang Z; Wu G; Kong W; Cheoklong NG; Tricard T; Wu X; Zhai W; Zhang W; Zhang J; Zhang D; Chen S; Lian Y; Chen Y; Zhang J; Huang Y; Xue W
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38862251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
    Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
    Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.
    Tanaka Y; Hatakeyama S; Hosogoe S; Tanaka T; Hamano I; Kusaka A; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Int J Clin Oncol; 2018 Feb; 23(1):134-141. PubMed ID: 28752352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Thrombus of Renal Cell Carcinoma Extending Into the Inferior Vena Cava, Ovarian Vein, and Ureter Treated With Neoadjuvant Axitinib.
    Komatsubara M; Yamazaki M; Fujisaki A; Kurokawa S; Morita T
    Urology; 2016 Sep; 95():e3-4. PubMed ID: 27292564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).
    Stewart GD; Welsh SJ; Ursprung S; Gallagher FA; Jones JO; Shields J; Smith CG; Mitchell TJ; Warren AY; Bex A; Boleti E; Carruthers J; Eisen T; Fife K; Hamid A; Laird A; Leung S; Malik J; Mendichovszky IA; Mumtaz F; Oades G; Priest AN; Riddick ACP; Venugopal B; Welsh M; Riddle K; Hopcroft LEM; ; Jones RJ
    Br J Cancer; 2022 Oct; 127(6):1051-1060. PubMed ID: 35739300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Presurgical Treatment with Axitinib and Pembrolizumab Reduced Operation Risk by Downsizing the Vena Cava Tumor Thrombus in Clear Cell Renal Cell Carcinoma : A Case Report].
    Inaba S; Sasaki T; Hattori Y; Terabe T; Kato M; Higashi S; Kato M; Masui S; Yoshio Y; Nishikawa K; Hayasaki A; Yamanaka T; Uchida K; Inoue T
    Hinyokika Kiyo; 2021 Oct; 67(10):443-447. PubMed ID: 34742168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
    Sassa N; Kato M; Funahashi Y; Maeda M; Inoue S; Gotoh M
    Jpn J Clin Oncol; 2014 Apr; 44(4):370-3. PubMed ID: 24571808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
    Lian B; Li Z; Wu N; Li M; Chen X; Zheng H; Gao M; Wang D; Sheng X; Tian H; Si L; Chi Z; Wang X; Lai Y; Sun T; Zhang Q; Kong Y; Long GV; Guo J; Cui C
    Ann Oncol; 2024 Feb; 35(2):211-220. PubMed ID: 37956739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
    Li S; Wu X; Yan X; Zhou L; Chi Z; Si L; Cui C; Tang B; Mao L; Lian B; Wang X; Bai X; Dai J; Kong Y; Tang X; Feng H; Yao S; Flaherty KT; Guo J; Sheng X
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant stereotactic ablative body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumor thrombus: a prospective pilot study.
    Chen J; Liu Z; Peng R; Liu Y; Zhang H; Wang G; Tian X; Pei X; Wang J; Zhang S; Wang H; Ma L
    BMC Urol; 2024 Feb; 24(1):31. PubMed ID: 38310214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
    Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
    Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
    Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W
    Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
    Lin Z; Xiao S; Qi Y; Guo J; Lu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.